Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Theranexus SA ( (FR:ALTHX) ) has provided an update.
Theranexus has disclosed the total number of shares and voting rights as of December 31, 2024, indicating transparency and compliance with financial regulations. This announcement provides stakeholders with crucial information about the company’s share structure, which can impact investor confidence and market positioning.
More about Theranexus SA
Theranexus is an innovative biopharmaceutical company originating from CEA, specializing in the treatment of rare neurological diseases. The company is focused on developing a unique platform for drug candidates targeting rare neurological disorders and currently has a drug candidate in clinical development for Batten disease. Theranexus is publicly traded on the Euronext Growth market in Paris.
YTD Price Performance: 4.81%
Average Trading Volume: 5,074
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €4.61M
Learn more about ALTHX stock on TipRanks’ Stock Analysis page.
